THE PATHOPHYSIOLOGICAL HYPOTHESIS OF HOMOCYSTEINE THIOLACTONE-MEDIATED VASCULAR DISEASE

被引:0
|
作者
Jakubowski, H. [1 ,2 ]
机构
[1] UMDNJ, Int Ctr Publ Hlth, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07101 USA
[2] Polish Acad Sci, Poznan, Poland
来源
关键词
autoantibodies; atherosclerosis; CBS; fibrinogen; hyperhomocysteinemia; homocysteine thiolactone hypothesis; immune activation; MTHFR; protein N-homocysteinylation; thrombosis;
D O I
暂无
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Accumulating evidence suggests that homocysteine (Hcy) metabolite, the thioester Hcy-thiolactone, plays an important role in atherothrombosis. Hcy-thiolactone is a product of an error-editing reaction in protein biosynthesis which forms when Hcy is mistakenly selected by methionyl-tRNA synthetase. The thioester chemistry of Hcy-thiolactone underlies its ability to from isopeptide bonds with protein lysine residues, which impairs or alters protein's function. Protein targets for the modification by Hcy-thiolactone include fibrinogen, low-density lipoprotein, high-density lipoprotein, albumin, hemoglobin, and ferritin. Pathophysiological consequences of protein N-homocysteinylation include protein and cell damage, activation of an adaptive immune response and synthesis of auto-antibodies against N-Hcy-proteins, and enhanced thrombosis caused by N-Hcy-fibrinogen. Recent development of highly sensitive chemical and immunohistochemical assays has allowed verification of the hypothesis that the Hcy-thiolactone pathway contributes to pathophysiology of the vascular system, in particular of the prediction that conditions predisposing to atherosclerosis, Such as genetic or dietary hyperhomocysteinemia, lead to elevation of Hcy-thiolactone and N-Hcy-protein. This prediction has been confirmed in vivo both in humans and in mice. For example, plasma Hcy-thiolactone was found to be elevated 59-72-fold in human patients with hyperhomocysteinemia secondary to mutations in methylenetetrahydrofolate reductase (MTHFR) or cystathionine beta-synthase (CBS) genes. Plasma N-Hcy-protein levels are elevated 24-30-fold ill MTHFR- or CBS-deficiency, both in human patients and in mice. Plasma and urinary Hcy-thiolactone and plasma N-Hcy-protein levels are also elevated up to 30-fold in mice fed a hyperhomocysteinemic (1.5% methionine) diet. Furthermore, plasma levels of pro-thromobogenic N-Hcy-fibrinogen were elevated in human CBS deficiency, which explains increased atherothrombosis observed in CBS-deficient patients. We also observed increased immunohistochemical staining for N-Hcy-protein in aortic lesions from ApoE-deficient mice with hyperhomocysteinemia induced by a high methionine diet, relative to the mice fed a normal chow diet. We conclude that genetic or dietary hyperhomocysteinemia significantly elevates proatherothrombotic metabolites Hcy-thiolactone and N-Hcy-proteins in humans and mice.
引用
收藏
页码:155 / 167
页数:13
相关论文
共 50 条
  • [41] Homocysteine and vascular disease: The role of folate, choline, and lipoproteins in homocysteine metabolism
    McCully, KS
    CHOLINE, PHOSPHOLIPIDS, HEALTH, AND DISEASE, 1998, : 117 - 130
  • [42] Role of aminothiols as a component of the plasma antioxidant system and relevance to homocysteine-mediated vascular disease
    Moat, SJ
    Bonham, JR
    Powers, HJ
    CLINICAL SCIENCE, 2001, 100 (01) : 73 - 79
  • [43] Endothelial- and leukocyte-mediated mechanisms in homocysteine-associated occlusive vascular disease
    Dudman, NPB
    Hale, SET
    HOMOCYSTEINE METABOLISM: FROM BASIC SCIENCE TO CLINICAL MEDICINE, 1997, : 267 - 271
  • [44] Homocysteine and Non-Cardiac Vascular Disease
    Katsiki, Niki
    Perez-Martinez, Pablo
    Mikhailidis, Dimitri P.
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (22) : 3224 - 3232
  • [45] Elevated plasma homocysteine and diabetic vascular disease
    Colwell, JA
    DIABETES CARE, 1997, 20 (12) : 1805 - 1806
  • [46] Homocysteine and hypomethylation - A novel link to vascular disease
    Lee, ME
    Wang, H
    TRENDS IN CARDIOVASCULAR MEDICINE, 1999, 9 (1-2) : 49 - 54
  • [47] Homocysteine - a novel risk factor for vascular disease
    Chambers, JC
    Seddon, MDI
    Shah, S
    Kooner, JS
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2001, 94 (01) : 10 - 13
  • [48] Plasma homocysteine and vascular disease in psychogeriatric patients
    Nilsson, K
    Gustafson, L
    Hultberg, B
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2006, 21 (03) : 148 - 154
  • [49] Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: An overview
    Castro, R
    Rivera, I
    Blom, HJ
    Jakobs, C
    de Almeida, IT
    JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 (01) : 3 - 20
  • [50] Key references: Homocysteine and atherothrombotic vascular disease
    Loscalzo, J
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2000, 9 (01) : 125 - 126